DE60325565D1 - Modifizierte saccharide mit verbesserter stabilität in wasser - Google Patents

Modifizierte saccharide mit verbesserter stabilität in wasser

Info

Publication number
DE60325565D1
DE60325565D1 DE60325565T DE60325565T DE60325565D1 DE 60325565 D1 DE60325565 D1 DE 60325565D1 DE 60325565 T DE60325565 T DE 60325565T DE 60325565 T DE60325565 T DE 60325565T DE 60325565 D1 DE60325565 D1 DE 60325565D1
Authority
DE
Germany
Prior art keywords
improved stability
water
modified
modified saccharides
polysaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60325565T
Other languages
German (de)
English (en)
Inventor
Paolo Costantino
Francesco Berti
Francesco Norelli
Antonella Bartoloni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines SRL
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics SRL
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0207117A external-priority patent/GB0207117D0/en
Priority claimed from GB0220195A external-priority patent/GB0220195D0/en
Priority claimed from GB0229494A external-priority patent/GB0229494D0/en
Priority claimed from GB0230163A external-priority patent/GB0230163D0/en
Application filed by Novartis Vaccines and Diagnostics SRL, Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics SRL
Application granted granted Critical
Publication of DE60325565D1 publication Critical patent/DE60325565D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DE60325565T 2002-03-26 2003-03-26 Modifizierte saccharide mit verbesserter stabilität in wasser Expired - Lifetime DE60325565D1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0207117A GB0207117D0 (en) 2002-03-26 2002-03-26 Modified saccharides having improved stability in water
GB0220195A GB0220195D0 (en) 2002-08-30 2002-08-30 Modified saccharides having improved stability in water
GB0229494A GB0229494D0 (en) 2002-12-18 2002-12-18 Modified saccharides having improved stability in water
GB0230163A GB0230163D0 (en) 2002-12-24 2002-12-24 Modified saccharides having improved stability in water
PCT/IB2003/001436 WO2003080678A1 (en) 2002-03-26 2003-03-26 Modified saccharides having improved stability in water

Publications (1)

Publication Number Publication Date
DE60325565D1 true DE60325565D1 (de) 2009-02-12

Family

ID=28457825

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60325565T Expired - Lifetime DE60325565D1 (de) 2002-03-26 2003-03-26 Modifizierte saccharide mit verbesserter stabilität in wasser

Country Status (14)

Country Link
EP (2) EP1777236B8 (enExample)
JP (2) JP2005526153A (enExample)
AT (1) ATE419278T1 (enExample)
BR (1) BR0308768A (enExample)
CA (1) CA2480389C (enExample)
CY (2) CY1108911T1 (enExample)
DE (1) DE60325565D1 (enExample)
DK (2) DK1490409T3 (enExample)
ES (2) ES2318117T3 (enExample)
HU (1) HUE030532T2 (enExample)
MX (1) MXPA04009339A (enExample)
NZ (1) NZ535968A (enExample)
PT (2) PT1490409E (enExample)
WO (1) WO2003080678A1 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
DE60328481D1 (de) 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
PT2191844E (pt) 2003-01-30 2014-06-04 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
RU2378010C2 (ru) 2003-10-02 2010-01-10 Новартис Вэксинес Энд Дайэгностикс С.Р.Л. Жидкие вакцины для множественных серогрупп менингококков
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
DK1740217T3 (da) 2004-04-30 2011-09-26 Novartis Ag Meningokok-konjugat-vaccination
EP1747457B1 (en) * 2004-05-20 2011-11-30 Novartis AG Analysis of liquid chromatography eluates
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
KR20070101207A (ko) * 2004-08-30 2007-10-16 사노피 파스퇴르 인크 다가 수막구균 유도체화된 다당류-단백질 접합체 및 백신
KR20070095868A (ko) * 2004-09-21 2007-10-01 사노피 파스퇴르 인크 다가 수막구균 유도체화된 다당류-단백질 접합체 및 백신
EP1885734B1 (en) * 2005-05-06 2015-01-14 Novartis AG Immunogens for meningitidis-a vaccines
GB0513071D0 (en) * 2005-06-27 2005-08-03 Glaxosmithkline Biolog Sa Immunogenic composition
WO2007000341A2 (en) * 2005-06-27 2007-01-04 Glaxosmithkline Biologicals S.A. Immunogenic composition
AU2006283302B2 (en) * 2005-08-24 2012-11-15 Novartis Vaccines And Diagnostics Srl Zwitterionization of capsular saccharides
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
DK2004225T3 (da) 2006-03-22 2012-08-06 Novartis Ag Programmer for vaccination med meningocockonjugater
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
AU2014200640B2 (en) * 2007-01-11 2016-06-16 Glaxosmithkline Biologicals Sa Modified saccharides
NZ581367A (en) 2007-06-04 2012-05-25 Novartis Ag Formulation of meningitis vaccines containing haemophilus influenzae and neisseria meningitidis
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
SI2200642T1 (sl) 2007-10-19 2012-06-29 Novartis Ag Formulacije meningokoknega cepiva
NZ587382A (en) 2008-02-21 2012-01-12 Novartis Ag Meningococcal fhbp polypeptides
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
CN102300585A (zh) 2008-12-17 2011-12-28 诺华有限公司 包含血红蛋白受体的脑膜炎球菌疫苗
ES2797504T3 (es) 2009-03-24 2020-12-02 Glaxosmithkline Biologicals Sa Proteína de enlace del factor H meningocócico utilizada como adyuvante
BRPI1009829A2 (pt) 2009-03-24 2016-11-16 Novartis Ag combinações de proteína de ligação de fator h meningocócico e conjugados de sacarídeos pneumocócicos
SG177310A1 (en) 2009-06-22 2012-02-28 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
PL2445522T3 (pl) 2009-06-22 2018-01-31 Wyeth Llc Kompozycje immunogenne antygenów Staphylococcus aureus
AU2010288240B2 (en) 2009-08-27 2014-03-27 Novartis Ag Hybrid polypeptides including meningococcal fHBP sequences
EP2483390A2 (en) 2009-09-30 2012-08-08 Novartis AG Expression of meningococcal fhbp polypeptides
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
SI2608805T2 (sl) 2010-08-23 2025-09-30 Wyeth Llc Stabilne formulacije antigenov rLP2086 neisserie meningitidis
US9057716B2 (en) 2010-09-04 2015-06-16 Novartis Ag Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines
BR112013005329A2 (pt) 2010-09-10 2017-05-02 Wyeth Llc variantes não lipidadas de antígenos orf2086 de neisseria meningitidis
ES2681698T3 (es) 2011-03-02 2018-09-14 Glaxosmithkline Biologicals Sa Vacunas de combinación con menores dosis de antígeno y/o adyuvante
JP6088507B2 (ja) 2011-07-08 2017-03-01 ノバルティス アーゲー チロシンライゲーションの方法
AU2012335208B2 (en) 2011-11-07 2017-08-31 Glaxosmithkline Biologicals S.A. Carrier molecule comprising a spr0096 and a spr2021 antigen
CA2862247A1 (en) 2011-12-29 2013-07-04 Novartis Ag Adjuvanted combinations of meningococcal factor h binding proteins
US20150125486A1 (en) 2012-03-08 2015-05-07 Novartis Ag Adjuvanted formulations of pediatric antigens
MX2018011291A (es) 2012-03-09 2023-01-31 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US9526776B2 (en) 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
WO2014095771A1 (en) 2012-12-18 2014-06-26 Novartis Ag Conjugates for protecting against diphtheria and/or tetanus
GB201300707D0 (en) * 2013-01-15 2013-02-27 Novartis Ag Compounds and processes
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
WO2015006728A2 (en) 2013-07-11 2015-01-15 Usera Aimee Site-specific chemoenzymatic protein modifications
BR112016004463A2 (pt) 2013-09-08 2017-10-17 Pfizer composições de neisseria meningitidis e métodos das mesmas
JP6786394B2 (ja) 2014-02-28 2020-11-18 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 改変髄膜炎菌ｆＨｂｐポリペプチド
WO2015158898A2 (en) * 2014-04-17 2015-10-22 Medizinische Hochschule Hannover Means and methods for producing neisseria meningitidis capsular polysaccharides of low dispersity
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3506933A2 (en) 2016-09-02 2019-07-10 GlaxoSmithKline Biologicals SA Vaccines for neisseria gonorrhoeae
AU2017321863B2 (en) 2016-09-02 2024-07-11 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
MX2022003682A (es) 2019-09-27 2022-04-25 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB733459A (en) * 1952-05-21 1955-07-13 Wander A G A Process for preparing stimulating agents for clinical use from bacterial polysaccharides
DE2748132A1 (de) * 1977-10-27 1979-05-03 Behringwerke Ag Stabilisator fuer polysaccharid
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
ATE121947T1 (de) * 1989-12-14 1995-05-15 Ca Nat Research Council Verbessertes meningokokkale polysaccharidkonjugatvakzin.
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
JP4162267B2 (ja) * 1996-08-27 2008-10-08 カイロン コーポレイション Ｎｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ血清型Ｂ複合糖質およびその使用法
CA2284606A1 (en) * 1997-03-26 1998-10-01 Brigham And Women's Hospital, Inc. Method for generating saccharide fragments
ES2346022T3 (es) * 1997-12-23 2010-10-07 Baxter Healthcare S.A. Procedimiento para la extraccion y el aislamiento de polisacaridos capsulares bacterianos para su uso como vacunas o ligandos a proteinas como vacunas de conjugados.
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines

Also Published As

Publication number Publication date
AU2003216633A1 (en) 2003-10-08
HUE030532T2 (en) 2017-05-29
CY1108911T1 (el) 2014-07-02
PT1490409E (pt) 2009-04-03
JP2010132925A (ja) 2010-06-17
ATE419278T1 (de) 2009-01-15
DK1777236T3 (en) 2017-02-27
WO2003080678A1 (en) 2003-10-02
MXPA04009339A (es) 2005-01-25
CA2480389C (en) 2012-10-09
EP1490409B1 (en) 2008-12-31
EP1490409A1 (en) 2004-12-29
CA2480389A1 (en) 2003-10-02
DK1490409T3 (da) 2009-03-23
ES2318117T3 (es) 2009-05-01
ES2616180T3 (es) 2017-06-09
JP5361767B2 (ja) 2013-12-04
EP1777236B8 (en) 2017-02-22
EP1777236B1 (en) 2016-11-30
PT1777236T (pt) 2017-02-13
BR0308768A (pt) 2005-02-15
CY1118584T1 (el) 2017-07-12
EP1777236A1 (en) 2007-04-25
JP2005526153A (ja) 2005-09-02
NZ535968A (en) 2006-08-31

Similar Documents

Publication Publication Date Title
ATE419278T1 (de) Modifizierte saccharide mit verbesserter stabilität in wasser
CY1113020T1 (el) Εμβολια συνδυασμου για neisseria meningitidis
SI2283857T1 (sl) Sestava cepiva, ki obsega konjugirane nativne kapsularne polisaharide n. meningitidis
DK1670506T3 (da) Flydende vacciner mod multiple meningococserogrupper
ZA200306176B (en) Multivalent meningococcal polysaccharide-protein conjugate vaccine.
BR0004128B1 (pt) folha fibrosa de múltiplas camadas, que se decompõe em água.
MA27047A1 (fr) Vaccination unidose avec mycoplasma hyopneumoniae.
DK1235589T3 (da) Præparater der omfatter neisseria meningitidis-antigener fra serogruppe B og C samt et yderligere antigen
DK1809661T3 (da) Humant interferon-beta-mutein
DE602005008380D1 (de) Sicherheitstinte
ITTO20020036A0 (it) Macchina operatrice, in particolare per movimento terra.
RU2003122317A (ru) Средство, повышающее иммуногенные свойства столбнячного анатоксина
BR0005675B1 (pt) conjunto formado por haste vazada-união roscada, para ser utilizado em extração de fluidos mediante acionamento de bombas rotativas.
ITRM20050628A1 (it) Tappezzeria trapuntata, con sorgenti luminose in corrispondenza delle impunture.
ES1051120Y (es) Mecanismo modificador del efecto sonoro en sordinas.
张星 No pains, no gains
ITAT20020002A1 (it) Persiana,in particolare persiana di legno.
ITTO20020214A1 (it) Macchina idro-operatrice, in particolare idrodemolitrice.
윤석임 Circular Infinity in James Dicky's Poetry
ITGE20030111A1 (it) Anta, in particolare per armadi e simili.
Liu Singing in the Viennese Woods
AU306690S (en) Slat support structure
ITMC20050030A1 (it) Spirale parallela rispetto a quella verticale tirante, fatta con una o piu' volute anche in coppia su ruota semovente.
ITAT20020001A1 (it) Serramento, in particolare serramento esterno di legno.
ITBS990088A0 (it) Coltivatore di ingombro riducibile.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition